triumph retatrutide produces up to 30.3% weight loss in Phase 3 trial A Study of Retatrutide (LY3437943)

Primary Handling Editor: Kaliya Georgieva

This means it activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor, a hormone pathway that helps the body release insulin after eating, which may lead to greater effects on blood sugar and weight loss compared to single GLP-1 agonists

As of late 2021, available evidence suggests first-line therapy with SGLT2 inhibitors may improve some outcomes, particularly in individuals with newly diagnosed diabetes and comorbid heart and kidney health concerns

This may lead to subtle changes such as: slightly increased appetite return of mild food cravings changes in blood sugar control for some individuals However, these effects typically occur gradually rather than suddenly

Some pharmaceutical companies offer patient assistance programs to help offset costs, especially for those without insurance